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Ramirez-Zamora et al. Proceedings of Fifth DBS Think Tank
The annual Deep Brain Stimulation (DBS) Think Tank provides a focal opportunity
for a multidisciplinary ensemble of experts in the field of neuromodulation to
discuss advancements and forthcoming opportunities and challenges in the field.
The proceedings of the fifth Think Tank summarize progress in neuromodulation
neurotechnology and techniques for the treatment of a range of neuropsychiatric
conditions including Parkinson’s disease, dystonia, essential tremor, Tourette syndrome,
obsessive compulsive disorder, epilepsy and cognitive, and motor disorders. Each
section of this overview of the meeting provides insight to the critical elements
of discussion, current challenges, and identified future directions of scientific and
technological development and application. The report addresses key issues in
developing, and emphasizes major innovations that have occurred during the past year.
Specifically, this year’s meeting focused on technical developments in DBS, design
considerations for DBS electrodes, improved sensors, neuronal signal processing,
advancements in development and uses of responsive DBS (closed-loop systems),
updates on National Institutes of Health and DARPA DBS programs of the BRAIN
initiative, and neuroethical and policy issues arising in and from DBS research and
applications in practice.
Keywords: deep brain stimulation, neuromodulation, epilepsy, Parkinson’s disease, tremor, obsessive compulsive
disorder, tourette syndrome, memory
INTRODUCTION
Neuromodulation, including cortical and subcortical approaches
for management of neurological and neuropsychiatric disorders,
continues to rapidly evolve. Technological advancements have
enabled an increased understanding of neuronal signals involved
in signs and symptoms of a number of neuropsychiatric
conditions. The Fifth Annual Deep Brain Stimulation (DBS)
Think Tank convened in Atlanta, GA, from May 19th to 21st,
2017 to address evolving applications, technological challenges
and future opportunities in neuromodulation. This report
highlights the challenges and opportunities addressed in the
meeting. There was particular focus on technical developments,
design considerations for DBS electrodes, emerging capabilities
of responsive DBS (closed-loop systems), updates from the
National Institutes of Health (NIH) and Defense Advanced
Research Projects Agency (DARPA) DBS-based programs, focus
upon advances and knowledge gaps in brain electrophysiology
and sensor technology, and address of ongoing and newly arising
neuroethical and policy issues generated in and by DBS research
and uses in practice.
TECHNICAL DEVELOPMENTS
Technologies Emerging Due to Investigator
Demand
Neuromodulation 2.0: Building a bridge from today’s tonic pulse
generators to tomorrow’s adaptive neurological “co-processors.”
The burden of neurological disease has significant economic
and societal impact. While neuromodulation-based therapeutic
devices have forged significant in-roads in treating some
neuropsychiatric conditions, overall, the relative success of such
approaches has been limited by fundamental questions regarding
the pathophysiology and mechanisms underlying both disease
processes and DBS-based interventions.
To address the extant knowledge gap, public and private
teams are collaborating on building and deploying investigational
research tools for studying the human nervous system in
both health and disease. The primary goal of this work is to
merge (basic and applied) biomedical research with engineering
design methods to catalyze the development of next generation
neuromodulation therapeutics (see Figure 1). The prototyping
of therapeutic concepts from a dynamic systems perspective has
fostered increased capability of bioelectronic systems that act
more as a neurological “co-processor” to address neural system
dysfunction, as opposed to the tonic, fixed-pattern stimulators
used to date. Emergent technologies include devices that store
event triggered recording and improved sensors capable of
recording local field potential (LFP) from an increased number
of channel combinations. Additional developments include an
enhanced capacity to parse signals from the neural noise floor,
development of embedded inertial sensors, use of advanced
stimulation parameters and patterns, creation of a rechargeable
battery (that can increase neurostimulator life to allow more
long term applications when utilizing advanced research tools),
production of upgradable and smaller devices, improved motion
sensing and distance telemetry (e.g., real-time streaming) with
higher throughput (not-compressed, multiple channels) and
research development kits (greater customization, integration
with local and distributed systems). External synchronization has
been a challenge in closed loop devices, and implanted device
technology with higher bandwidth than current systems has the
potential to improve synchronization and to better detect the
fast dynamics of neural signals of interest. Toward this end,
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FIGURE 1 | Toolboxes to promote translational neuromodulation research and discovery.
newer networks can select recordings and set specific signals
to improve synchronization. The potential release of second-
generation devices (e.g., the Medtronic RC+S) for use in certain
National Institutes of Health (NIH) projects funded under the
United States’ Brain Research through Advanced Innovative
Neurotechnology (BRAIN) Initiative may address some of these
needs. As well, the limited number of lead contacts for closed
loop applications has been a constraint. Newer devices will likely
facilitate the ability to sample two channels per lead; the use of
additional channels could be beneficial to both increase sampling
and to pair stimulation in closed-loop devices.
Highlights and Future Directions
• Emerging technological developments include improved
sensors, increased device memory, and rechargeable batteries.
• Development of external signals to improve closed loop
synchronizations has been identified as being important to
next-generation technology capability.
• An increased number of lead electrodes may improve both
stimulation and recording capacities of both current and newly
developing devices.
Variable Frequency Stimulation as a New
Approach to DBS in Defined Applications
There are ongoing efforts to define particular signs and symptoms
of neuropsychiatric disorders that may be mitigated by DBS
intervention. Freezing of gait (FOG) is defined as a sudden
arrest of forward stepping commonly affecting patients with
advanced Parkinson’s disease (PD) (Nutt et al., 2011). Occurrence
and management of FOG is challenging as FOG is often
resistant to levodopa treatment in patients with advanced PD.
In small case series, low frequency stimulation (LFS) of the
subthalamic nucleus (STN) (60–80Hz) has provided short term
benefit in reducing axial symptoms including FOG, although
this has raised concerns about the worsening of appendicular
symptoms, in particular tremor (Xie et al., 2015; Zibetti et al.,
2016). A novel DBS paradigm that combined high and low
frequency stimulation in varying patterns (VFS) to address FOG
and appendicular PD motor symptoms has been proposed (Jia
et al., 2017). Following an open label, doubled blind design,
investigators utilized the PINS DBS system to assess the effect
of VFS in FOG (NCT02601144). The study included twenty-
eight (28) PD subjects presenting with FOG, who were implanted
with bilateral STN DBS. At baseline, patients were evaluated
under four DBS conditions: DBS off, LFS (60–80Hz), HFS
(130–180Hz) and VFS for a total of 6 h. All subjects were
discharged home on VFS settings and were scheduled for a
follow-up second study visit after 6 months, and for a final
evaluation at 12 months. Changes in the Unified Parkinson’s
Disease (UPDRS) motor scale and a 10-meter timed up-and-
go (TUG) task were assessed at baseline, and following 1 h of
high, low, and VFS. Chronic VFS therapy was assessed at 6 and
12 months with the FOG questionnaire and the gait and falls
questionnaire. Initial data suggests that VFS was well tolerated
and that it reduces appendicular symptoms and the number of
FOG episodes compared to HFS and LFS at 12 months follow up.
Finalized publication of the data is pending.
Highlights and Future Directions
• A novel VFS DBS programming paradigm was shown to elicit
improved benefit over traditional HFS and LFS programming
in an open label design study.
• VFS was well tolerated and was shown to potentially reduce
FOG episodes and improve TUG measures.
• The use of external sensing triggered by physiological changes
indicative of FOG might be useful a specific biomarker to best
utilize VFS.
Biphasic DBS for Essential Tremor and
Dystonia
Despite advances in DBS techniques and technology, clinicians
continue to face limitations in battery longevity and in
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stimulation-induced side effects. The conventional DBS
waveform consists of a rectangular biphasic pulse, with an
active, high-amplitude and short-duration phase, followed by a
passive, low amplitude, charge-balancing phase. Pilot research at
the University of Florida in movement disorders reported that
square biphasic (sqBIP) pulses (with active rather than passive
charge-balancing phase) were well tolerated and provided a
greater clinical benefit when compared to commercially available
DBS (Akbar et al., 2016).
An open label, pilot trial assessed (over a period of hours)
the safety and tolerability of sqBiP DBS in patients with PD, ET,
and dystonia (Almeida et al., 2017). Secondary analysis included
effects on motor response produced by sqBiP DBS compared
to conventional stimulation. Firmware was updated with
proprietary software provided by the manufacturer (Medtronic).
Patients were tested in at-home settings (conventional DBS), after
a 30-min washout, and then at multiple time points after sqBiP
DBS was implemented for a total of 3 h for ET and PD, and 2 h
for dystonia.
At each evaluation, motor behavior and scales were
videotaped, and accelerometer and GAITRite data were
collected. There were no adverse events documented in either
arm of the study. Significantly positive changes in tremor scores
over time, and in accelerometer data were observed. Subsequent
post-hoc analysis showed significance only between different
time points and the washout period. For treatment of dystonia,
there was a significant change in cervical dystonia scores, with
post-hoc analysis revealing differences between other time points
and the washout. Interestingly, there was a gradual improvement
in GAITRite measures, including cadence, velocity, average
step length, and double support time with sqBiP stimulation.
sqBiP was well-tolerated in the acute ambulatory setting, with
possibly similar benefits produced in motor scores and improved
cadence, step stride, and double support gait assessments.
Highlights and Future Directions
• A novel stimulation technique, sqBiP adjusted the pulse
frequency and shape of pulses.
• In use against ET, sqBiP DBS improved tremor scales and
accelerometer parameters. In treating dystonia sqBiP DBS
produced an improvement in gait variables.
• Future studies will explore the mechanisms of sqBiP pulses;
long term outcomes; battery consumption, and clinical
benefits in treatment of ET, PD, dystonia and other select
disorders.
Distributed Network Control with High
Density Neuromodulation Technology for
the Treatment of Intractable Epilepsy
Anterior thalamic DBS (Salanova et al., 2015) and responsive
neuromodulation (Bergey et al., 2015) for treatment epilepsy
has been reported to show an approximately 65% reduction in
seizures at long term follow-up. Preliminary data using an in vitro
multi-electrode array in cell culture revealed that asynchronous
multi-site stimulation eliminated synchronous epileptogenic
activity. Furthermore, in animal models, multi-microelectrodes
were more effective than macroelectrodes in terminating seizures
through the use of asynchronous theta stimulation (Desai et al.,
2016). While such animal studies are promising, it was suggested
that the use of a non-human primate model of penicillin induced
seizure) would be important (and thus is planned) prior to
considering use of this approach in human patients.
A translational study using RC+S (Medtronic) is also
currently planned to identify electrophysiological biomarkers
and to integrate a closed-loop approach. The initial phase of
our studies aims to use an external system to test stimulation
in an open loop fashion using asynchronous distributed
microelectrode theta stimulation.We will also record biomarkers
and use these to design a closed loop neuromodulation algorithm.
This will lead in phase 2 to a translational NHP study using RC+S
(Medtronic) which will allow both open-loop and closed-loop
algorithms based on the previous experiment. The third phase
will translate the NHP findings into an early stage feasibility
study in epilepsy patients. These studies rely on novel high-
channel count electrodes, bidirectional neurostimulation devices
and novel computational approaches.
Highlights and Future Directions
• Preliminary data using in vitro multielectrode array in
cell culture revealed asynchronous multi-site stimulation
eliminated synchronous epileptiform activity.
• Multi-microelectrodes were more effective than
macroelectrodes in terminating seizures in a rodent model
using asynchronous theta stimulation.
• Using an acute non-human primate seizure model of epilepsy,
the research will attempt to translate the above findings, and
to identify biomarkers to be used in implementation of closed
loop seizure control optimization.
ADVANCES IN CLOSED LOOP DBS
Parkinson’s Disease
Closed Loop DBS in PD
Specific examples of the application of closed-loop DBS in
PD are growing (Rosin et al., 2011; Little et al., 2013, 2016;
Malekmohammadi et al., 2016). These cases have demonstrated
symptom improvement, with substantial power savings and/or
reduction in side-effects attributable to stimulation. The feedback
substrates and closed-loop control algorithms involved have
varied, but most have relied on the amplitude of beta activity
as directly recorded in the basal ganglia-cortical loop. The
amplitude of such beta activity correlates with bradykinesia
and rigidity and is suppressed by both medications that exert
effect on central dopaminergic activity, and high frequency DBS
(Meidahl et al., 2017). Thus far, closed-loop control algorithms
have either engaged an on-off activity pattern, with short
ramping onset and offset (see Figure 2), or have employed
a more gradual, proportional or hybrid control policy. One
important consideration is the optimal reactivity of the closed-
loop system, which may impact its efficacy, efficiency and
ultimate therapeutic window. In healthy primates, and in patients
with PD, beta activity is phasic (Tinkhauser et al., 2017). Longer
bursts attain higher amplitudes, indicative of more pervasive
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oscillatory synchronization within the neural circuit. Shorter
bursts predominate in healthy states; and in patients, the relative
proportion of short and long bursts negatively and positively
correlate with motor impairment, respectively. Therefore, it
might be best to selectively terminate longer, (i.e., pathological)
beta bursts through closed-loop DBS to both maximize power
savings and to spare the ability of underlying neural circuits
to engage in more physiological processing which may involve
shorter bursts (Tinkhauser et al., 2017).
The role of more complex feedback signals, including
multidimensional central and peripheral inputs, remains to be
explored, as do the advantages of more sophisticated control
algorithms. In particular, it may prove necessary to tailor control
loops to afford improved amelioration of patient-specific patterns
of impairment (Meidahl et al., 2017). On the other hand,
one of the factors constraining the development of closed-loop
DBS is the range of possible feedback signals, control policies,
and stimulation patterns. Arguably, the field needs to focus
on demonstrating an unequivocal gain over conventional DBS
before closed-loop DBS techniques are further nuanced. The key
will be to shift from acute trials in post-operative patients—
where studies are confounded by stun effects and temporal
constraints – to acute and then ultimately to chronic trials in
patients who have already undergone conventional DBS. The
latter will allow resolution of the stun effect, and will afford time
for optimization of conventional DBS so that valid comparisons
can be made. However, these types of chronic trials will require
further development of enabling technology, together with a
more informed understanding of the dynamics of target circuits.
Highlights and Future Directions
• In PD, beta activity is phasic with longer busts attaining
higher amplitudes, indicative of more pervasive oscillatory
synchronization within the neural circuit. Shorter bursts
predominate in the healthy state, and the relative proportion of
short and long bursts negatively and positively correlate with
motor impairment, respectively.
• Termination of longer, pathological beta bursts through
closed-loop DBS might maximize power savings, and spare
the ability of underlying neural circuits to engage in more
physiological processing.
• The next steps in adaptive DBS involves shifting from acute
trials in post-operative patients to longer assessment and
evaluation to minimize confounded factors.
Customizing Control Variables and Control Policy
Algorithms for Closed Loop DBS to Treat Tremor in
Parkinson’s Disease
At present DBS is characteristically provided as continuous,
open loop, non-responsive input, and uses a “one-size fits all”
set of parameters for a wide range of neurological disorders. It
cannot respond to the patient’s state (asleep/awake, rest/active),
dominant symptoms (tremor, bradykinesia, gait impairment)
or medication level. In contrast, closed loop (i.e., responsive)
DBS (CL– DBS) for PD, using kinematic and/or neural
biomarkers, has the potential to deliver more precise and
customized neuromodulation, based on state, symptom and level
of medication. To be successful CL-DBS requires feedback signals
(control variables) that are accurate reflections of the disease
state or symptom, and neuromodulation paradigms (control
policy algorithms) that are customized for that disease/symptom.
Tremor is especially well-suited for responsive or CL-DBS as it
varies in amplitude or presence over time and differs between PD
subjects. CL-DBS for tremor can be approached using control
variables such as a peripheral measure of tremor (Kinematic
Cl-DBS) or the STN LFP beta band (13–30Hz) power (Neural
CL-DBS) (Malekmohammadi et al., 2016). Attenuation of STN
beta band power by medication or DBS is associated with
improvement in both rigidity and bradykinesia and has been the
control variable used in CL-DBS studies to date (Kuhn et al.,
2008; Whitmer et al., 2012). However, the presence of tremor
itself may attenuate beta band power and thus Neural CL-DBS
may not be useful for tremor (Shreve et al., 2017).
The effectiveness and efficiency of Kinematic compared to
Neural CL-DBS and to open loop DBS were determined in six PD
subjects (Malekmohammadi et al., 2016) using a dual threshold
control policy algorithm, (Figure 3), for either beta band power,
(Figures 3A,B), or tremor power, measured by a Bluetooth
enabled smartwatch (Figure 3C). Voltage was increased if either
beta or tremor power was above the upper threshold, remained
the same if between thresholds, and was decreased if below
the lower threshold. Both techniques improved tremor to a
similar degree; Kinematic CL-DBS used 10.6% of the total energy
that would have been delivered (TEED) during open loop DBS
and Neural CL-DBS used 31.5% TEED. Kinematic CL-DBS was
significantly more efficient than Neural CL-DBS (P < 0.05).
Neural CL-DBS was efficacious in treating tremor if the initial
voltage was in a therapeutic range; whereas Kinematic CL-DBS
required tremor to be present and initial voltage was set at the
lower therapeutic limit. This research demonstrates that CL-
DBS, using either a neural or kinematic control variable, is more
efficient than open loop DBS. Furthermore, it highlights the
potential that additional development of patient- and symptom-
specific control variables, and control policy algorithms will
improve the efficiency, efficacy and specificity of DBS therapy
for PD.
Highlights and Future Directions
• Tremor in PD is a symptom especially well-suited for
responsive or closed loop DBS as it varies in amplitude or
presence over time and differs between patients.
• In a pilot trial, there were no differences between tremor
control with adaptive DBS using Kinematic or Neural CL-DBS
and Kinematic CL-DBS was significantly more efficient than
Neural CL-DBS KCL-DBS.
Closed-Loop DBS for Freezing of Gait in PD
Levodopa-resistant posture, and FOG symptoms are disabling
and difficult to address in patients with PD. Recent DBS trials
have rarely addressed FOG and specifically “on-medication”
freezing and falling. Freezing appears to involve some
GABA-ergically-mediated activity of the globus pallidus
Frontiers in Neuroscience | www.frontiersin.org 5 January 2018 | Volume 11 | Article 734
Ramirez-Zamora et al. Proceedings of Fifth DBS Think Tank
FIGURE 2 | The beta burst duration and amplitude as a potential biomarker for closed loop approaches. On-off feedback control of beta activity recorded in the
subthalamic nucleus in a patient with PD so as to terminate long duration, high amplitude beta bursts. Intermittent stimulation may be sufficient to improve motor
impairment, whilst sparing more physiological periods of processing and thereby limiting side-effects (Tinkhauser et al., 2017 with permission).
interna (GPi) that leads to dysfunction of the pedunculopontine
nucleus (PPN). Human DBS studies have targeted the PPN or the
PPN plus STN with mixed—and in many cases, unsatisfactory
outcomes (Stefani et al., 2007; Moreau et al., 2009; Moro et al.,
2010). However, there is no consensus regarding the best PPN
target and both rostral and caudal pedunculopontine nucleus
subregions have been targeted (Thevathasan et al., 2017). There
is great variability in clinical methodology used among surgical
centers and the spread of stimulation and inconsistency in
targeting suggests that neighboring brain stem regions may be
implicated in any DBS response. Because of the intermittent
nature of FOG, a feasibility closed-loop neuromodulation
(CL-DBS) approach for bilateral PPN DBS plus conventional
bilateral open-loop DBS (OL-DBS) of the GPi to manage
on-medication FOG in PD has been initiated at the University
of Florida. Five patients with advanced PD and refractory FOG
were implanted with Medtronic Activa PC+S implantable
neurostimulators leads. The patients were carefully evaluated,
so as to define true “on” medication freezers. A closed-loop
PPN DBS paradigm has been developed using LFPs occurring
in GPi and PPN during normal walking and during maneuvers
known to trigger freezing episodes. Assessments are blinded
and videotaped including objective gait laboratory analysis. PPN
CL-DBS was aimed to deliver stimulation at different frequencies
(5, 25, 65, and 130HZ) at the onset of gait. This PPN CL-DBS
paradigm was also used for long-term PPN CL-DBS via the
Nexus-E firmware, which allows similar Nexus-D operation,
but is a completely embedded, enclosed system with no external
triggers or machines. GPi stimulation settings were determined
by clinical benefit consistent with current standard of care for
optimizing pallidal DBS. The study remains ongoing and will
report safety and feasibility of this approach along with clear
neurophysiological changes in beta and theta bands that could be
potential biomarkers to guide future adaptive DBS approaches.
Highlights and Future Directions
• A novel closed loop DBS system that targets GPi and PPN is
currently investigated for treatment of refractory “on” FOG in
PD patients. Approach appears safe and applicable.
• Challenges will include establishing the most effective location
of PPN contacts, and programming settings, identifying
reliable neurophysiological biomarkers of walking and FOG,
and refining patient selection in light of wide variability among
advanced PD patients.
Closed Loop Deep Brain Stimulation for PD: Update
on Use of Cortical Control Signals
Currently used DBS devices generally deliver “open loop”
stimulation, continuously stimulating target structures regardless
of changes in the brain circuits related to disease expression.
Device programming is a labor-intensive process that is based on
“trial and error” and requires significant clinical expertise, which
are barriers to widespread clinical application. Additionally,
continuous open-loop DBS for PD may result in suboptimal
control of fluctuating motor signs, stimulation-induced adverse
effects, and short battery life (Little et al., 2016).
As previously noted, one approach is to utilize subthalamic
beta band activity as the control signal for closed loop
stimulation (Little et al., 2013). Advantages of this approach
include conceptual simplicity, and that the control signal can be
derived from the same electrode array as used for therapeutic
stimulation, thereby obviating the need for additional sensor
electrodes. Disadvantages include a relatively low amplitude
signal with high stimulation artifact, and that the beta band
activity is strongly affected by normal movement, not just
the severity of Parkinsonian motor signs (Qasim et al., 2016).
We have developed an alternative technique for closed loop
stimulation in PD using a sensor that is permanently implanted
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FIGURE 3 | The Development of a Closed Loop System for PD Tremor. (A) Voltage dependent attenuation of STN beta band power; top panel- time frequency
spectrogram, black bars indicate periods of STN DBS; lower panel group averaged relative beta band power at different DBS voltages. (B) Dual threshold control
policy diagram; βREST–beta power no DBS at rest; βU, βL–beta power at lower and upper limits of DBS voltage; βINC, βDEC–beta power of upper and lower
thresholds. (C). Example of STN KCL-DBS using dual tremor power thresholds (lower panel blue and magenta lines). DBS voltage (upper panel) follows tremor power
and remains off for much of the trial when there is no tremor.
in the subdural space over the primary motor cortex. This
is attached, along with the ipsilateral subthalamic stimulating
lead, to an investigational pulse generator (Activa PC+S,
Medtronic) with sensing as well as stimulation capability that
can be used to prototype feedback control algorithms. The
control strategy is based on detection of a narrow band
gamma oscillation (60–90Hz) that has previously been shown
to be a biomarker of the dyskinetic state (Swann et al., 2016)
(Figure 4).
We have tested this method in three phases (1) in vitro
experiments using previously collected cortical signals converted
to analog voltages and applied to a saline bath containing a paddle
lead attached to an external PC+S; (2) in the clinic, streaming
data from an implanted PC+S to an external laptop that
controlled the PC+S stimulus via radiotelemetry (Herron and
Chizeck, 2014), and (3) in a second clinical application, which
evaluated the control algorithm totally embedded in PC+S.
In two test subjects, closed loop control (Nexus E) provided
26 and 39% reduction in energy delivered, without adverse
effects. Patients in this study did not perceive stimulation-
related changes. Cortical contacts were implanted through the
same DBS burr hole and appeared to be stable in the long-
term (as observed in other recent studies conducted at multiple
sites).
Highlights and Future Directions
• A new technique aims to optimize electrophysiological signals
used for closed loop DBS using a sensor permanently
implanted in the subdural space over primary motor cortex.
• Utilizing an investigational pulse generator (Activa PC+S,
Medtronic), the control strategy is based on detection of a
narrow band gamma oscillation (60–90Hz) previously shown
to be a biomarker of the dyskinetic state.
• Future challenges include identifying the most effective type
of detection; selecting the best type of signal; noise reduction;
identifying the ideal frequency band; and discerning between
use of single vs. multiple frequencies.
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FIGURE 4 | Using Gamma Power as a Biomarker for Closed Loop Deep Brain Stimulation. A brief trial of closed loop stimulation using a cortical detector in a patient
with intermittent dyskinesia in spite of therapeutic STN DBS. This trial was implemented with data streaming from PC+S to an external computer (using Nexus D2/3).
Top: spectrogram of motor cortex ECoG signal over 300 s, showing several epochs of an 80Hz oscillation heralding the dyskinetic state. Bottom: transitions in
stimulation triggered by the 80Hz oscillation. Red line depicts the gamma power envelope at 80Hz center frequency and 5Hz bandwidth. Gold line depicts the
detector that classifies gamma power to high or low values. Blue line depicts spectral power at stimulation frequency (160Hz). When average gamma power (over
10 s) exceeded or dropped below a threshold (2.5 × standard deviation of gamma power during a calibration recording), stimulation was decreased, or increased,
respectively.
Deep Brain Stimulation for Other
Neuropsychiatric Conditions
Tourette Syndrome
Tourette syndrome (TS) is a developmental neuropsychiatric
disorder characterized by involuntary and vocal tics, which is
commonly co-morbid to other conditions, such as attention
deficit hyperactivity disorder and obsessive compulsive disorder
(Cheung et al., 2007; Kenney et al., 2008). The etiology
of TS remains largely unknown; however, a commonly
accepted hypothesis implicates dysfunction of corticostriatal and
thalamocortical circuits (Albin and Mink, 2006). DBS is an
emerging therapy for cases of severe and intractable TS, and
next generation DBS devices, such as the Neuropace RNS and
Medtronic Activa PC+S, provide tools with which to record
electrophysiological signals that can be used to study network
effects and pathophysiology in this disorder.
Two studies of TS electrophysiology using DBS have recently
been conducted at the University of Florida. The first implanted
dual DBS leads in the centromedian- parafascicular complex
of the thalamus, and employed a NeuroPace RNS device both
to study electrophysiology of tics and to develop a responsive
neurostimulation paradigm. Responsive DBS was achieved in
one subject, delivering stimulation in response to increases in
low-frequency activity (5–15Hz) in the thalamus that correlated
with dystonic tics (Molina et al., 2017). A second study, using
the Medtronic Activa PC+S devices targeted the same thalamic
nucleus bilaterally, but also included bilateral cortical subdural
strips over the motor cortex to study the thalamocortical network
of tic generation (Shute et al., 2016).
Long complex tics were shown to be concurrent with a
consistently detectable low frequency activity in the thalamus, as
shown in other studies. However, stimulation artifacts resulted
in the development of a responsive DBS based on the cortical
signatures of tic generation, which involved increases in cortical
beta activity (Shute et al., 2016). An ongoing NIH study is
examining the physiology of tics and closed loop DBS in 10
human subjects. Resetting tic mechanisms to achieve a more
normal pattern of oscillatory activity may reduce tics and also
lead to less device discharge over longitudinal follow-up.
Highlights and Future Directions
• Pilot studies of responsive neurostimulation in TS patients
have been conducted and a larger trial is currently underway.
• Neural activity precedes tic onset, and successful stimulation
results in cortical phase amplitude coupling.
• Future challenges—and opportunities—include developing
consistent programming algorithms, improving stimulation
settings, achieving higher resolution tic detection, and defining
additional biomarkers.
Optimizing Neurophysiologic DBS Signal for
Treatment of Tourette Syndrome
LFP analysis is a well-established method for investigating
disease, and network and stimulation dynamics in PD. Analysis
of intraoperative basal ganglia LFPs can potentially predict the
optimal stimulation contact (Ince et al., 2010). There is increasing
interest in the use of DBS to treat signs and symptoms of TS, and
multiple DBS targets have been proposed for the treatment of TS
(Viswanathan et al., 2012). LFP analysis using signals captured
from a combination of DBS electrodes and cortical recordings has
previously shown thalamocortical activity changes during tics in
TS (Shute et al., 2016). Limited data exist about the role of LFPs
in the posteroventral GPi in TS, although open label stimulation
at this site does seem to improve symptoms (Shahed et al., 2007).
LFP recordings from the GPi during an intraoperative testing
paradigm capturing the resting state, voluntary movements,
and tic activity have been analyzed and reported in 3 subjects
with TS (Jimenez-Shahed et al., 2016). The LFP data filtered
between 13 and 30Hz indicated the presence of event related
desynchronization with lower amplitude beta band oscillations
during tic periods compared to the resting state. During tic
periods, there was also amplitude enhancement in the gamma
range (40–150Hz) and higher frequencies (150–500Hz) in
all subjects. Subjects demonstrated individual changes in the
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spectral power of LFPs in both the low and high frequency
oscillations (HFO) during different states. The resting state was
further characterized by coupling between the phase of theta-
low alpha oscillations to the amplitude of HFOs in two subjects,
while tic activity was associated with beta-HFO phase-amplitude
coupling (PAC) in all 3 subjects. These results were in contrast
to the novel identification of beta-HFO PAC in the GPi of four
un-medicated PD patients at rest. These findings suggest that
tic activity can be neurophysiologically distinguished (at the
subcortical level) from rest, voluntary movements and akinesia,
and that the GPi is a viable target for neuromodulation to
decrease tics in TS. Additionally, these data challenge the view
that beta-HFO PAC is only a marker of akinesia, since tics
represent a hyperkinetic state. These results also highlight the
importance of investigating the HFO range of LFP activity.
Given these findings, we posit that continuing investigation
of the LFP spectral characteristics and non-linear interactions
between different LFP frequency bands across nodes within
the basal ganglia-thalamo-cortical network in TS (and other
movement disorders) will broaden understanding of the
neurophysiologic abnormalities characterizing these conditions.
This knowledge will also contribute to the identification of the
most appropriate and sensitive signals to trigger closed loop
stimulation when different movement patterns are present.
Highlights and Future Directions
• LFP recordings from the GPi demonstrate individual changes
in the spectral power in both the low and HFO sub-band
during different rest, voluntary movements or tics.
• Tic activity was associated with beta-HFO phase-amplitude
coupling in this study.
• Continued investigation of the LFP spectral characteristics
of different movement disorders will contribute to the
identification of the most appropriate and sensitive signals to
trigger and to develop closed loop stimulation.
Studying Oscillatory Activity in Deep Brain
Stimulation for Depression
DBS of the subcallosal cingulate white matter (SCCwm) has
been shown to elicit durable improvements in depressive
symptoms (Riva-Posse et al., 2017). Here, preliminary work is
presented that characterizes network-level electrophysiological
changes in patients with treatment-resistant depression whowere
implanted with SCCwm-DBS. Using a prototype bi-directional
DBS platform that employed the Activa PC+S (Stanslaski et al.,
2012) in conjunction with dense array EEG, preliminary evidence
of electrophysiologic changes in the SCC and downstream
cortical regions was demonstrated that correlated with both the
disease state and stimulation conditions.
In order to assess the validity of any oscillatory biometric
captured from patients with chronically implanted prototype
devices, preliminary evaluations focused upon limitations of
oscillatory analyses in the context of technical device capabilities.
In particular, it is known that amplifier limitations are sensitive to
disease-independent tissue impedances and impedance changes.
Thus, amplifier-related distortions present in bi-directional DBS
devices during stimulation were modeled in order to identify
potential spurious oscillatory results. Non-linear gain responses
from an amplifier that is engaged to its output limits can result
in strong high-frequency oscillations and low-to-high phase-
amplitude coupling spuriously because of soft-clipping of the
input signal. In light of this, we are developing an interactive
tool that can be used to assess level of gain compression making
analysis and interpretation of oscillatory results more reliable.
Modern analytical approaches were employed to overcome
challenges that result from both recording noise and low
patient sample sizes. Next, we utilized a machine learning-based
algorithm to extract oscillatory biometrics in the chronic PC+S
recordings. This approach, when learned on limited, noisy data
in a training set, is able to predict the current level of depression
severity (asmeasured by weekly rating scales) with approximately
50% correlation in a testing set of patients. This strategy appears
to have technical, analytical, and practical advantages given
the limited number of patients, sparseness of sampling, and
the known trajectory of clinical depression response(s). This
approach, when complemented with standard Fourier-domain
approaches, can help to identify useful models for biometrics
construction that can be based on correlative analyses.
Despite promising initial results, the exact mechanism of
action of SCCwm-DBS still remains unclear, but appears
to involve cortical regions beyond the site of stimulation
(Mayberg et al., 2005). Using multimodal electrophysiology, we
are therefore investigating rapid, transiently induced cortical
oscillatory responses to connectomics-optimized SCCwm-DBS.
In all patients with simultaneous PC+S LFP and dense EEG,
alpha power change patterns can be used to clearly separate
stimulation at the optimal SCC contact from stimulation at
an adjacent contact on the DBS lead just 1.5mm away. The
complementary accuracy and reliability of this method in
confirming current tractographic approaches is the focus of
ongoing studies employing a larger cohort.
Highlights and Future Directions
• Various approaches can be used to identify putative biometrics
of depression and anatomic sites and networks that be
employed in future closed-loop DBS to objectively confirm
proper anatomical targeting and potentially optimize
therapeutically effective parameters of DBS in treatment of
depression.
• Assessment, iterative modification, and expanded testing-set
validation will be continued in ongoing investigations with
additional subjects.
• Future opportunities will focus upon identifying stimulation
settings that will reproduce the putative biomarkers observed
on EEG.
Central Thalamic Stimulation for Traumatic Brain
Injury (TBI)
Involvement of the central thalamus has been implicated in
the pathophysiology of certain types of traumatic brain injury
(TBI). As this area links to other relevant brain networks and
regions, the involvement of the central thalamus may play
an important—and reciprocal—role in other brain responses
to TBI, as well. Neural networks mediating arousal project
Frontiers in Neuroscience | www.frontiersin.org 9 January 2018 | Volume 11 | Article 734
Ramirez-Zamora et al. Proceedings of Fifth DBS Think Tank
to the central thalamus, with efferent projections to the
anterior forebrain (Schiff, 2016). Pre-clinical animal (non-human
primate—NHP) and rodent) models have elucidated these
central thalamic to forebrain connections and their functional
activation using electrophysiologic methods and optogenetic
techniques combined with fMRI (Liu et al., 2015; Baker et al.,
2016). Proof of concept that DBS of the central thalamus can
produce improvements in cognitive performance and arousal
supports the further development of clinical studies (Giacino
et al., 2012). Additional studies in human patients withminimally
conscious state showed that central thalamic DBS produced
improvement(s) in bothmotor and cognitive function. Notably, a
single-subject in minimally conscious state demonstrated motor
and cognitive improvement with central thalamic DBS; this
patient regained capacity to identify objects and speak after an
initial titration phase along with improvements in attention and
organized activity of the upper limb. Oral feeding was greatly
improved with DBS as well. A clinical trial targeting patients with
persistent cognitive difficulties after TBI is planned. Six patients
with severe to moderate brain injury (GOSE Outcome level 6–
7) at least two years following their initial injury with persistent
cognitive impairment limiting regaining vocation and social
reentry will be enrolled. The primary outcomes measure will
test attention and working memory function. EEG will be used
as a secondary physiological marker of cognitive impairment in
order to examine physiological mechanisms of DBS effects and to
potentially develop adaptive technologies.
Highlights and Future Directions
• Preclinical and clinical data support the role of the central
thalamus and its projections in arousal and attention.
• A clinical trial aiming to assess the effect of central thalamic
DBS in patients with TBI is underway. Cortical recordings
and correlates of cognitive function will be explored using
recording DBS technology and EEG.
• Challenges include establishing definitive anatomical
substrate(s) for stimulation, selecting ideal candidate patients,
obtaining neuroimaging assessments, and developing and
implementing the most effective and reliable programming
techniques.
Adaptive DBS for Obsessive Compulsive Disorder
(OCD)
Ventral Striatum (VS) DBS has FDA humanitarian device
exemption approval for treatment of intractable OCD, and
has been shown to incur 60% clinical benefit in recent meta-
analysis (of open-label studies) (Alonso et al., 2015). However,
management and programming strategies are increasingly
challenged to provide persistent benefit while limiting the
occurrence of DBS-induced behavioral side effects, most notably
hypomania (Widge et al., 2016). Programming adjustments have
been made largely on the basis of acquiring acute beneficial
effects on outcome measures of “anxiety reduction,” “improved
mood” and “increased energy.” Induction of “mirth” has served
as a guidepost measure to programming, and has been regarded
as predictive of good response to treatment (Haq et al., 2011).
However, DBS-induced mirth also represents a potential risk for
development of hypomania or mania. Thus, there is a clear need
for an adaptive DBS (aDBS) system that can correctly assess
hypomania as distinguished from a euthymic mood state, and
automatically adjust stimulation accordingly.
A pilot study funded by the NIH BRAIN Initiative aims to
develop and to test a prototype aDBS system for intractable OCD
that uses LFP signals to automatically adjust DBS parameters to
both improve symptom management and reduce stimulation-
induced behavioral side effects. One of the challenges of this study
was to identify a label for the classifiers that was objective, reliable,
and fitting the National Institute of Mental Health (NIMH)
Research Domain Criteria (RDoC) Constructs. Positive Valence
(e.g., for elevated or euthymic mood) and Negative Valence
Constructs (e.g., to encompass depression, anxiety, and disgust
associated with worsening OCD) were selected, with facial affect
being used to represent the motor output of emotional state;
a measure considered to be superior to clinician ratings of
affect for tracking changes in real time. The automated facial
affect recognition (AFAR) platform (Tian et al., 2001) will be
utilized, and time-locked with inputs from LFPs, EEG, motion,
physiology, and changes in DBS programming in order to build
classifiers for use in this, and future studies.
Highlights and Future Directions
• Ongoing studies are underway toward the development of
adaptive technology that can provide accurate classification
of acute fluctuations in obsessive ideation and/or compulsive
behaviors that can be used to improve DBS programming for
use in treatment of OCD.
• The use of an automated facial recognition program will be
evaluated as a potential biomarker of emotional state and to
determine feasibility for use in adaptive control.
• Challenges include determining how the system can separate
physiologic from pathological states, and if and how the system
can adequately classify numerous behavioral signals.
Brain State Monitoring for Closed Loop Epilepsy
Epilepsy is an epidemiologically common neurological disease
and over 1/3 of patients have drug resistant epilepsy. In select
cases, neurosurgical intervention can cure focal epilepsy, but
many patients are not surgical candidates because their seizures
are poorly localized or originate from brain regions that cannot
be safely resected. Seizures are generally treated as random
events, and there are currently no proven surrogate biomarkers
for seizures. Clinicians must select a treatment and titration
plan (drug, dose, stimulation parameters, etc.) based on clinical
guidelines, and then wait for a treatment failure to make further
treatment adjustments.
Advances in neural engineering have led to implantable
devices capable of therapeutic electrical stimulation (Fisher
and Velasco, 2014), seizure detection and forecasting (Cook
et al., 2013). Electrical stimulation of the anterior nucleus
of the thalamus (Fisher et al., 2010; Salanova et al., 2015)
and responsive stimulation of detected electrophysiological
abnormalities (Morrell and RNS System in Epilepsy StudyGroup,
2011; Heck et al., 2014; Bergey et al., 2015) were shown to reduce
seizure burden in well-designed pivotal trials, but patients rarely
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achieved complete seizure freedom. Recently, multiple groups
have demonstrated the feasibility of seizure forecasting in both
humans (Park et al., 2011; Cook et al., 2013; Brinkmann et al.,
2016) and canines (Howbert et al., 2014; Brinkmann et al.,
2015) using intracranial EEG. Seizure forecasting has also been
demonstrated in ambulatory patients with an implantable device
that provides continuous intracranial EEG (iEEG) integrated
with a personal assistant device (PAD), running both seizure
detection and forecasting algorithms (Cook et al., 2013). Next
generation implantable devices are now poised to transform
epilepsy management by integrating brain sensing, active brain
probing, seizure detection, electronic seizure diaries, seizure
forecasting, and intelligent therapeutic stimulation.
The fact that seizure probability fluctuates opens the
possibility of directly tracking seizure probability and
dynamically adjusting therapy to prevent seizures. Furthermore,
it has been shown that the neuronal assemblies activated during
seizures may be consolidated in post-seizure slow-wave sleep,
i.e., physiological learning mechanisms may strengthen the
seizure engram (Bower et al., 2015). This observation suggests
targeting neuronal dynamics during post-seizure slow-wave
sleep as a brain state dependent therapy. Thus, devices providing
continuous brain sensing, probing, and intelligent stimulation
based on seizure probability and brain state can open new
therapeutic options. In addition, the ability to directly interact
with the nervous system could open a new era of brain research.
For example, the RC+S (Bourget et al., 2015) is a rechargeable
device, with sensing, stimulation, embedded computational
payloads, and continuous iEEG telemetry that affords capability
of distributed computing & analytics on a hand-held PAD and
cloud environment. It is also rechargeable. Currently pre-clinical
development and validation of RC+S in dogs with naturally
occurring epilepsy is underway and a human feasibility trial is
planned for early 2019 (Figure 5).
Highlights and Future Directions
• There is a need for developing better tools to precisely identify
and analyse seizures. Neuronal ensembles during seizures
using scalp EEG have shown that neurons that fire together (at
the onset of seizure), wire together (during slow wave sleep).
• Utilizing advanced DBS devices, a currently initiated
preclinical study aims to continuously stream EEG data to
detect anomalies in epilepsy, and improve seizure forecasting
and detection.
DBS ELECTRODES
Electrochemistry of Deep Brain Stimulation
Electrodes
The purpose of DBS electrodes is to artificially manipulate
neural activity by generating an electric field in the tissue,
ultimately resulting in a redistribution of charged particles in
the extracellular space. Ideally, the electrode charge is injected
capacitively, so that electrons are not transferred between the
electrode-tissue interface and charge is rearranged in the tissue
in response to the injected charge on the electrode side. The
FIGURE 5 | Next Generation Epilepsy Therapy Platform. The implanted,
rechargeable Medtronic RC+S provides bi-directional coupling with the
brain in patients with epilepsy. The personal assistant device (PAD) provides
off-the-body analytics and is bi-directional with a cloud environment. The figure
is adapted from Cook et al. with permission (Cook et al., 2013 with permission).
amount of charge injected is transferred via an electron transfer
process (i.e., a faradaic reaction), and capacitive reactions occur
as well (Merrill et al., 2005). Undesired faradaic reactions
include electrode dissolution products that diffuse into tissue
(Figure 6).
Balancing the amount of charge injected during the
stimulation phase by a subsequent phase of the opposite
polarity was formerly thought to avoid undesirable faradaic
reactions. However, imbalanced charge biphasic waveforms
are now known to reduce the amount of platinum (Pt)
electrode dissolutionwhen compared to balanced charge biphasic
waveforms (Kumsa et al., 2016). In addition to minimization
of Pt dissolution, imbalanced charge biphasic waveforms extend
the parameter space that could be explored for current
steering to selectively activate a target brain region during
DBS therapy. More often than not, selection of stimulation
parameters is made under consideration for thresholds of tissue
damage. While there is no recognized standard addressing
safe levels of stimulation, the Shannon plot has been used
to set charge and charge density limits. Acute animal data
collected used to establish the Shannon plot implies that
tissue damage might be dependent on charge injection and
surface area of the electrode used. These considerations may
guide future selections of electrode materials and/or stimulation
parameters.
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FIGURE 6 | The electrode-electrolyte interface. A schematic representation of the electrode-electrolyte interface [from (Merrill et al., 2005 with permission) far left]. The
concentration of Pt measured at different charge densities for cathodic-first (middle) and anodic-first (far right) stimulation waveforms (Kumsa et al., 2016 with
permission).
Highlights and Future Directions
• Design considerations for DBS electrodes should incorporate
the needs of different spatial and temporal resolutions.
• Charge considerations include safety limits for charge density
to avoid tissue damage that can be further characterized by
animal studies to demonstrate:
◦ Shannon plots of tissue damage thresholds (30 uC/cm2
warning derived from Shannon plot at 50Hz); and
◦ Charge-balanced biphasic waveforms.
• The threat of stimulation-induced damage has been shown to
be dependent on charge injection and the surface area of the
electrode.
Biophysics of Recording through Deep
Brain Stimulation Electrodes
LFP recordings from DBS electrodes represent an exciting
opportunity to study pathological activity in neurological
disorders and to provide a potential control signal for closed-
loop DBS systems. In PD, these LFP recordings have shown
pathological hyper-synchrony within the beta frequency range
(e.g., 13–30Hz) and the oscillations can be reduced with
therapeutic DBS (Kuhn et al., 2008; Bronte-Stewart et al., 2009).
Closed-loop stimulation using the beta-band LFP as a control
signal has demonstrated the potential to improve both the
efficiency and possibly the efficacy of DBS (Little et al., 2013;
Rosa et al., 2015). New implantable systems can also perform
both stimulation and recording through DBS leads (Kuhn and
Volkmann, 2017).
Although LFP recordings have the potential to provide disease
biomarkers and a control signal for closed-loop stimulation,
the origin of the LFP is poorly understood. Because clinical
applications of the LFP (e.g., to optimize implant location)
exploit the spatial dimensions of the LFP and relative changes in
its frequency content (Zaidel et al., 2010), successful application
of LFP recordings requires accurate interpretation of the source,
recording volume, and various experimental factors (e.g., non-
ideal properties of the recording system).
In general, the LFP is believed to be dominated by
postsynaptic currents (Kajikawa and Schroeder, 2011).
Previous experimental studies with intracortical microelectrodes
suggested that the LFP only extends a few 100µm (Katzner
et al., 2009) while contradictory evidence suggest that the
LFP can extend several millimeters (Kajikawa and Schroeder,
2011). A computational modeling study showed that the LFP
spatial reach is not simple or stationary, but depends on a
number of variables, such as neuron morphology, and the
distribution and correlations in synaptic activity (Linden et al.,
2011). A computational model to specifically characterize LFP
recordings from DBS electrodes was previously developed
(Lempka and Mcintyre, 2013). Using this model, it was
determined that the LFP can extend several millimeters and that
its spatial reach was dependent on factors such as the spatial
distribution of correlated synaptic activity and the recording
configuration, but was independent of the electrode impedance
(see Figure 7).
To further increase the clinical utility of this modeling
approach, a patient-specific LFP model to estimate the
region of beta hyper-synchrony within the STN was
developed. The model demonstrated that the size and
shape of correlated activity within the STN and its relative
location to the DBS lead dramatically affect the recorded
LFP. It is believed that this patient-specific modeling
approach represents an excellent tool to study the neural
underpinnings of clinical LFP recordings and to help provide
the knowledge necessary to develop effective closed-loop DBS
technologies.
Frontiers in Neuroscience | www.frontiersin.org 12 January 2018 | Volume 11 | Article 734
Ramirez-Zamora et al. Proceedings of Fifth DBS Think Tank
FIGURE 7 | LFP recordings from DBS electrodes. (A) Correlated synaptic activity dominates the LFP and determines its spatial reach. A DBS electrode is shown
implanted in the center of a volume of STN neurons. Neurons within a population radius (R ≤ Rcorrelated) receive highly synchronous synaptic inputs while the
remaining neurons (R > Rcorrelated) receive uncorrelated synaptic inputs. Within correlated regions, an increase in the population radius produces a linear increase in
the amplitude of the LFP. Outside of the correlated volume, there is no significant increase in the LFP amplitude. (B) Recording configuration effects on the LFP. In this
example, all neurons receive correlated synaptic inputs. For a monopolar recording (red electrode only), the LFP amplitude increases linearly with an increase in the
population radius and does not converge to a maximum value. However, a bipolar recording (red electrode—blue electrode) limits the amplitude and spatial reach of
the LFP recording.
Highlights and Future Directions
• The origin of the LFP is poorly understood with conflicting
information regarding LFP’s spatial reach.
• A previous computational model determined that the LFP
can extend several millimeters and that its spatial reach was
dependent on factors, such as the spatial distribution of
correlated synaptic activity and the recording configuration,
but was independent of the electrode impedance.
• A new computational model demonstrated that the size and
shape of correlated activity within the STN and its relative
location to the DBS lead dramatically affect the recorded LFP.
• Understanding the neural mechanisms of clinical LFP
recordings is necessary to develop effective closed-loop DBS
technologies. Future research will focus on determining the
LFP construct, LFP interpretation based on electrode position,
changes in new directional leads and variation over time.
Coupled Theoretical and Experimental
Analysis of DBS Electrodes
Nearly all DBS leads implanted to date consist of a stack of
four cylindrical electrode contacts. More recently, directional
DBS leads with electrode contacts segmented along and around
the lead body have shown utility for more selective targeting of
neural pathways of interest while avoiding activation of neural
pathways implicated in DBS side-effects (Buhlmann et al., 2011;
Martens et al., 2011; Keane et al., 2012; Zitella et al., 2013; Pollo
et al., 2014) (See Figure 8). Computational models that integrate
realistic tissue bioelectrics and cellular biophysics provide a
useful framework to assess the design and performance of these
directional DBS lead designs.
While many directional DBS lead designs have been proposed,
computational models suggest that designs incorporating 3–4
radial electrodes used in concert with multi-channel independent
current-controlled stimulation provide a good balance of (1)
maintaining safe current density limits when using smaller
electrodes at therapeutic stimulation amplitudes; and (2)
requirements for higher channel counts to enable better shifting
and sculpting of the activation volumes around a DBS lead
(Teplitzky et al., 2016; Figure 8). Further, computational models
have also shown that directional DBS leads canmove the center of
mass of axonal activation by (at most) 1–1.3mm tangential to the
lead shaft (Teplitzky et al., 2016). This suggests that directional
DBS leads, while an enabling technology, may not be able to
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FIGURE 8 | Programming of directional DBS lead designs. Conventional and directional DBS lead designs targeting the subthalamic nucleus for the treatment of
Parkinson’s disease. Computational programming algorithms can accommodate multiple regions of interest such as the dorsolateral subthalamic nucleus (dl-STN)
and the superior cerebellar peduncle (SCP) as well as multiple regions of avoidance, i.e., the corticospinal tract within the internal capsule (IC). Shown is an example of
a Pareto Front resulting from the particle swarm optimization algorithm approach to identify stimulation settings that maximize activation in regions of interest and
minimize activation of regions of avoidance. Images courtesy of Edgar Peña, Julia Slopsema, and Matthew Johnson (with permission).
rescue therapy for DBS leads that are implanted significantly
(>1–1.3mm) off target. Models also suggest that axonal tracts
oriented parallel, in comparison to perpendicular, to the applied
electrical field will have lower activation thresholds (Lehto et al.,
2017). Such orientation selectivity might help with structural
leads design and avoid adverse side effects with DBS.
Once a DBS lead is implanted, stimulation settings are
typically tested in a trial-and-error process by stimulating
through combinations of electrode contacts to identify
stimulation settings that optimize the therapeutic effect based
upon clinical outcome measures (Volkmann et al., 2006). Recent
developments in subject-specific computational bioelectric
models and visualization of the predicted neuronal pathways
activated have shown promise in identifying DBS settings that
avoid inducing side effects (Frankemolle et al., 2010; Chaturvedi
et al., 2013) Leveraging these computational models, several
novel semi-automated programming algorithms have been
advanced to assist with the selection of stimulation parameters.
These algorithms have a basis in machine learning (Chaturvedi
et al., 2013; Teplitzky et al., 2016), convex optimization
theory (Xiao et al., 2016), and most recently particle swarm
optimization (Peña et al., 2017), which allow clinicians to
use multiple objectives in their identification of optimal DBS
settings.
Highlights and Future Directions
• Computational models support the safety of designs
incorporating 3–4 radial electrodes used in concert
with multi-channel independent current controlled
stimulation.
• Computational bioelectric models and visualization of the
predicted neuronal pathways activated have shown promise in
identifying DBS settings to deliver therapy and avoid inducing
side effects.
• Orientation selective DBS that leverages directional lead
technology is poised to improve clinical outcomes (Lehto et al.,
2017).
• Future clinical implementation of direction leads will
likely leverage novel semi-automated programming
algorithms to assist with the selection of stimulation
parameters.
DBS TARGETING AND METRICS
Noninvasive Biomarkers to Advanced
Emerging DBS Electrode Technologies
Directional DBS electrode technology, as available from multiple
vendors, is now entering the commercial market. However, there
is a lack of robust tools with which to efficiently implement
increasingly adaptable and complex DBS systems. To address this
problem, new putative biomarkers to measure patient-specific
cortical activation patterns elicited by DBS with combined
electroencephalography and electrocorticography (EEG/ECoG)
have been investigated.
Clinical applicability of effective contacts with a new
directional lead incurs a number of challenges, including the
number of contacts to be used, potential combinations of
contacts, and complex interactions with anatomical structures.
Therefore, a goal is to innovate new approaches to tailor
DBS programming adjustments in individuals and to more
rapidly arrive at effective, well-tolerated stimulator settings with
directional lead technology by using software to remove stimulus
artifacts. This should facilitate measurement of fast dynamics of
brain responses where there is a short latency to stimulation of
the cortex. Such knowledge will be important and useful (1) to
better understand the concept of DBS dose, and this may have
broad applications for the development of minimally invasive
biomarkers; (2) to refine surgical targeting of the DBS electrode
in real time; and (3) to inform emerging closed loop stimulation
strategies.
Highlights and Future Directions
• Technological advances are aimed at developing
adaptable devices and biomarkers to measure patient-
specific cortical activation patterns elicited by DBS with
combined electroencephalography and electrocorticography
(EEG/ECoG).
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• There is a need to continuously develop and improve
effective and simple stimulation settings, surgical targeting,
and manipulation of the field of stimulation.
• Questions remain regarding the effects of different stimulation
settings among different structures in the basal ganglia (and
elsewhere).
Temporal Pattern of Stimulation Is a New
Dimension of Therapeutic Innovation
In the course of experiments intended to test the hypothesis
that the reductions of symptoms by DBS required regularization
of the firing patterns of neurons (Grill et al., 2004), it was
discovered that the effects of DBS were strongly dependent on
the temporal pattern of stimulation. Specifically, randompatterns
of subthalamic nucleus DBS were not as effective as regular
frequency DBS at relieving motor symptoms in the 6-OHDA
lesioned rat model of PD (Mcconnell et al., 2016) or in humans
with PD (Dorval et al., 2010). Similarly, random patterns of
thalamic DBS were not as effective as regular frequency DBS at
relieving tremor in persons with essential tremor (Birdno et al.,
2007, 2008, 2012). In addition to supporting the importance
of regularization of neural firing to the efficacy of DBS, this
finding inspired the idea of explicitly designing temporal patterns
of stimulation to increase the efficacy and energy efficiency
of DBS.
However, the design space for temporal patterns is
enormous—for example a 200ms duration train, composed
of 1ms bins each which may or may not contain a pulse, results
in 1050 different possible patterns of stimulation. Therefore,
a model-based design approach employing computational
evolution to design optimized temporal patterns of stimulation
was developed. Computational evolution works analogously
to biological evolution, and the organisms in this approach
are temporal patterns of stimulation, and the fitness of any
particular pattern is evaluated using a model-based proxy for
symptoms (Brocker et al., 2017). Thus, an innovative approach
to make a temporary direct connection to the brain lead during
surgical replacement of the battery-depleted implantable pulse
generator (IPG) (Swan et al., 2014), and to conduct short-
term intraoperative testing of the model-optimized patterns.
The results demonstrated that the optimized patterns either
addressed bradykinesia more effectively than conventional
regularly patterned DBS (Brocker et al., 2013), or enabled
equivalent treatment of bradykinesia but with a substantial
reduction in the required energy (Brocker et al., 2017). This
latter finding is important, as it enables increases in the battery
life of IPGs, reduction in IPG size, or longer intervals between
recharging.
Subsequently a start-up company, Deep Brain Innovations,
Inc. conducted a multi-center double-blinded trial comparing
temporally optimized patterns of stimulation to conventional
high frequency DBS. The results of this study demonstrated
that temporally optimized patterns of stimulation produced
equivalent or better symptom reduction and substantially
reduced energy requirements. In addition to their promise to
improve DBS therapy for PD, these data suggest that the temporal
pattern of stimulation might be a new dimension of therapy
parameter adjustment that can be exploited in other applications
of neuromodulation.
Highlights and Future Directions
• The effects of DBS were strongly dependent on the temporal
pattern of stimulation and computational models can provide
optimized patterns to improve efficacy or improve efficiency.
• Optimized patterns improved bradykinesia more effectively
than conventional regularly patterned intraoperative DBS.
• Preliminary results showed that stimulation was well tolerated
and produced equivalent or better symptom reduction and
substantial reduced energy requirement in some patients.
Using Human Connectome Data to Map
Deep Brain Stimulation Targets
Stereotactic targeting of the anterior limb of the internal
capsule (ALIC) has been used for decades to treat patients
with refractory OCD, depression, and other neuropsychiatric
disorders. However, there is uncertainty about optimal targeting
within the ALIC, as different locations appear to have variable
efficacy/effectiveness. Using diffusion tensor imaging (DTI),
the ALIC was anatomically segmented based on prefrontal
connectivity in order to evaluate the effect of various stereotactic
targets.
ALIC segmentations based on frontal Brodmann area (BA)
connectivity were generated and combined for 40 subjects from
the Human Connectome Project (HCP) using connectivity-
based seed classification (Nanda et al., 2017). A literature review
revealed five stereotactic targets within the ALIC. Targets were
modeled as 5mm spheres and were evaluated for overlap with
various DTI-defined ALIC segments. Deterministic tractography
was performed on an 842-subject HCP DTI template using
modeled targets as seeds to identify involved connectomic
networks (Figure 9).
FIGURE 9 | DTI modeled structural connectivity. Tracts running through the
five modeled targets (colored spheres in the diagram) according to the HCP
842-subject diffusion data template.
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All 40 ALIC segmentations exhibited a dorsal-ventral axis
of organization. On average, the combined segmentation was
accurate for 66.2% of individuals. The region assigned to BA11
(orbitofrontal cortex, OFC) exhibited the greatest consistency
across individuals, with 12.1% being consistently assigned in all
40 subjects. According to the segmentation, a mean of 63.9%
of modeled lesion volume within the ALIC intersected with the
BA11 region. All five modeled targets exhibited connectivity to
OFC in the 842-subject HCP template.
These results clarify the organization and variability of
the ALIC. This variability suggests that patients may benefit
from pre-operative tractography for individualized targeting,
although current stereotactic targets tend to involve the most
consistent ALIC sub-regions. These findings also suggest that
stereotactic targeting within the ALIC likely involves modulation
of prefrontal-subcortical tracts connecting the OFC, which bears
relevance to the cortico-striato-thalamo-cortical (CSTC) model
of neuropsychiatric pathophysiology.
Highlights and Future Directions
• The Anterior limb of the internal capsule (ALIC) is a frequent
DBS target for treatment of psychiatric diseases.
• Using a DTI-based template from the Human Connectome, a
study was undertaken to map this region to better understand
these tracts for DBS application.
• This research demonstrated that the ALIC has a general
axis of orientation but variability is present and can be
probabilistically quantified (some loci show differences).
RAD-PD: Registry for the Advancement of
DBS in Parkinson’s Disease
PD DBS is well known to improve motor function and
quality of life in patients experiencing motor complications.
However, numerous questions remain about best practices
related to DBS, which cannot be answered through traditional
clinical trials methods. The Registry for the Advancement of
DBS in Parkinson’s Disease (RAD-PD) has been proposed
as a partnership between the Parkinson Study Group (PSG),
Neuropoint Alliance (NPA) and Neurotargeting, LLC, to
establish a quality improvement (QI) registry for DBS.
The QI design of RAD-PD will allow for continuous
benchmarking of selected data and the opportunity to review
those findings via regular dash-boarding and discussion at
periodic study group meetings. The registry can support research
functions, secondary analysis, linkage to other databases, sub-
studies analysis, data collection and use of a de-identified dataset
to answer research questions. Multiple clinical questions that
cannot otherwise be practically answered will be investigated
regarding the best practices surrounding DBS therapy, adverse
effects of DBS (and their determinants), the health economics
of PD DBS, as well as the correlates of disparities in outcomes
among individuals receiving the therapy (Figure 10).
The project design has potential to gather longitudinal,
prospective data from over 1,000 participants with PD across a
5-year period of DBS therapy, with a data collection and analysis
period of up to 10 years. The project is currently under review
FIGURE 10 | RAD-PD: Registry for the Advancement of DBS in Parkinson’s
Disease. The RAD-PD data elements include clinician-measured and
patient-reported outcomes (indicated by *), which will be collected at baseline
(pre-operatively), 6 months, 1 year, and annually through 5 years. The total
project period will last 10 years.
for funding. Once implemented, the potential exists to extend the
RAD-PD infrastructure for the capture and analysis of similar
data from patients with other conditions being treated with DBS.
Highlights and Future Directions
• The Registry for the Advancement of DBS in Parkinson’s
Disease (RAD-PD) is a DBS Registry for PD to address
numerous clinical questions.
• The registry would integrate different groups for analysis
including Neurotargeting, Neuropoint Alliance, and the
Parkinson’s Study Group (PSG).
• The registry will focus on a Quality Improvement Registry
utilizing a data-driven approach.
Diagnostic Data Management in
Closed-Loop Cortical Stimulation for
Epilepsy
The RNS R© System is an FDA approved therapy for treating
medically refractory partial onset epilepsy in individuals 18
years of age or older (Bergey et al., 2015). The RNS System
consists of an implantable neurostimulator and leads (depths
or strips), a physician operated programmer, a patient operated
remote monitor and a secure website referred to as the
Patient Data Management System (PDMS). The neurostimulator
records data of frequency, timing, and location of electrographic
activity specific to each patient. The neurostimulator also stores
electrocorticograms (ECOGs) as well as counts and timing
of various events (detected patterns, long duration events,
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high amplitude events and magnet placements). These data
are collected via the physician programmer and the patient
operated remotemonitor to provide a long-term record of patient
electrographic activity. These data are then organized and made
available for clinician review via the PDMS (Figure 11).
In the clinical care environment, physicians must be able
to quickly assess data trends and make programming changes
within the constraints of a typical clinic visit. The PDMS provides
concise summary data and capabilities to quickly sort and view
classes of ECOGs and graph trends of various events. It also
allows physicians to determine detection settings by clicking
on ECOG locations of epileptiform activity they intend to
detect. The system then runs a series of algorithms to suggest
initial settings. The clinician can rapidly review the suggested
settings performance against the library of stored ECOGs
and make adjustments to achieve the detection performance
desired.
Highlights and Future Directions
• NeuroPace PDMS (Patient Data Management System) allows
remote storage on data bank and can simulate detection rate
based on the parameter selection and previously data.
• The PDMS provides concise summary data capabilities to
quickly sort and view classes of ECOGs and to graph trends
of various events to determine detection settings by clicking
on ECOG locations of epileptiform activity.
FEDERAL INITIATIVES
Updates on DBS Directions from the NIH
P50 Udall Program
NIH Udall Center grants aim to foster multidisciplinary work
with nine centers around the United States. Despite years
of clinical success and efforts to improve clinical outcomes,
the degree of therapy achieved with DBS varies widely
among patients for both STN DBS and GPi DBS (Deep-Brain
Stimulation for Parkinson’s Disease Study Group et al., 2001).
Such variability across centers and within any given center likely
stems from multiple factors, including patient phenotype(s),
assessment protocol, patient health, DBS target, DBS lead
location within the target, and the stimulation parameters used
to deliver the therapy (Kleiner-Fisman et al., 2006).
To address these challenges, the NIH recently awarded a
Morris K. Udall Center of Excellence for Parkinson’s Disease
Research grant to the University of Minnesota (PI: Jerrold L.
Vitek). The University of Minnesota’s (UMN) NIH Udall Center
is focused on understanding the electrophysiological features that
underlie individual motor signs of PD and developing new DBS
strategies to treat these motor signs more effectively and more
consistently. This is being accomplished in humans through a
combination of intra-operative microelectrode, externalized lead
recordings, post-operative LFP recordings using the Medtronic
RC+S “Brain Radio,” and DBS therapy implemented through
the lens of novel targets and stimulation paradigms. These
FIGURE 11 | Defining Pattern feature in PDMS. The clinician clicks on the ECOG in the top panel and the PDMS suggests initial detection settings that are
immediately simulated in the bottom panel. Sliders in the middle panel allow the physician to make adjustments to achieve the desired performance.
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data will be complemented by electrophysiological studies in
preclinical animal models of Parkinson’s disease with directional
DBS implants, and by the development and electrophysiological
characterization of optimization tools for improving subject-
specific precision of DBS therapy.
Highlights and Future Directions
• The UMN NIH Udall Center is focused on understanding the
electrophysiological features that underlie individual motor
signs of PD and in developing and advancing new DBS targets
and stimulation paradigms through a combination of intra-
operative microelectrode and post-operative LFP recordings.
• Specific goals of the UMN Udall Center include:
◦ Project 1 (Human): Understand PD pathophysiology as it
relates to DBS.
◦ Project 2 (Human): Identify mechanisms and pathways
mediating the motor effects of pallidal DBS.
◦ Project 3 (Pre-clinical Research):
Identify electrophysiological mechanisms underlying
the clinical variability with DBS therapy for Parkinson’s
disease.
High Bandwidth Wireless Interfaces in
Quadraplegia
The BrainGate consortium is a multi-center effort to restore
communication and movement capabilities to people with
paralysis and to develop next generation neurotechnologies. The
study has recruited 13 participants with over 9,310 total implant
days. A completely implantable brain computer interface has
also been developed for potential future human use, toward
neurally controlled point-and-click (keyboard, communication
devices) and for multi-dimensional control of robotic assistive
devices or one’s own arm and hand. Patients with severe
neurological motor disability from ALS, brainstem stroke,
or cervical spinal cord injury have demonstrated impressive
control of communication and mobility technologies. The core
technology, consisting of the decoding of ensembles of single
neurons, could provide a neurophysiological signature that could
be deployed as part of a closed loop neuromodulation device
in both neurologic or psychiatric disorders. Wireless arrays
record broad band intracortical physiology and are able to
provide external responsive stimulation to contracting implanted
muscles. In the future, wirelessly connected cortical arrays
capable of recording broadband intracortical signals will also be
able to direct the movement of functionally electrical stimulation
systems for the restoration of limb movement. The long term
aims of the BrainGate trial are to neuroengineer improved BCI
capabilities; communicate the validity and viability of BCI-based
approaches to both the medical community and representative
stake-holders (i.e., patients and the public), and assist and restore
function to patients in need.
Highlights and Future Directions
• BrainGate is a multicenter effort dedicated to restoring
movement capabilities to motor-impaired individuals. The
initiative initially focused on achieving decoding accuracy, and
this is being extended by research into improvements in the
efficiency of filter calibration and adaptation.
• Future challenges include designing of devices that are
portable, fully implanted, compact, wireless, and available
around-the-clock to support useful applications and activities
of daily living.
• Important questions and challenges remain regarding the
number and configuration of electrodes, methods to assess the
stability of decoders, personal assessments (to each patient)
that balance the risks vs. potential performance as compared
the risk/benefit provided by BCIs that record from the scalp.
Updates from DARPA: Restoring Active
Memory (RAM)
Neurotechnology: Bridging the Gap between Mind
and Machine
DARPA’s innovations in neurotechnology are making possible
real-time, seamless translation between human brains and
machines. These technologies have enabled initial approaches
that enable analyses of the ways that diffuse and varied
signals from arrays of firing neurons affect brain function.
DARPA’s current investments in neural interfaces and related
technologies build upon this understanding of neural encoding
and decoding, developing multi-scale computational models
with high spatial and temporal resolution to target a variety
of neurologic functions, and these research approaches are
synergized by studies that address engineering challenges of
designing implantable, closed-loop systems. Key DARPA-funded
capability demonstrations include controlling and receiving
feedback from a prosthetic arm using sensors in the motor and
somatosensory cortices; receiving feedback from a virtual hand
using implants in peripheral nerves; and improving declarative
memory through stimulation of specific brain regions. DARPA’s
work is establishing a basis of what is currently possible, revealing
how neurotechnology could facilitate symbiotic human-machine
interfacing, and engaging assessment and address of the
ethical, legal, social, and policy issues fostered by emerging
neurotechnologies (see also, below).
Modulating Human Memory Using Direct Brain
Stimulation
The Restoring Active Memory (RAM) project aims to develop
implantable therapies to treat veterans with TBI by increasing
their ability to encode information. In this study, the hypothesis
that targeted electrical stimulation can modulate neural
encoding states and subsequent memory outcomes was tested.
Using recordings from neurosurgical epilepsy patients with
intracranially implanted electrodes, multivariate classifiers were
trained to discriminate spectral activity during the encoding of
words that predicted whether patients would later remember or
forget these words; and stimulation was applied to various brain
regions to modulate performance.
It was found that stimulation modulates performance,
with large variability across the population and across the
various brain regions stimulated. Hippocampal stimulation
tended to impair recall performance while lateral temporal
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FIGURE 12 | The effect of stimulation is dependent on brain state. Recall
performance increased if stimulation was delivered when the brain was in a
low encoding state (p < 0.03) and decreased if delivered in a high encoding
state (p < 0.05). The difference between low and high stimulation was also
significant (p < 0.003). Red bars show mean SE of the difference.
cortex stimulation significantly improved recall performance. In
addition, stimulation increased recall performance if delivered
when the classifier indicated low encoding efficiency but
had the reverse effect if stimulation was delivered when the
classifier indicated high encoding efficiency (Figure 12). These
data suggest strategies for therapeutically treating memory
dysfunction using closed-loop brain stimulation.
Highlights and Future Directions
• Electrical stimulation canmodulate neural encoding states and
subsequent memory outcomes.
• The timing of stimulation and strict anatomical targeting
appear critical to enhance memory. Developing patient-
specific classifiers and stimulation patterns that adjust over
time might provide sustained benefits.
• Current work provides proof of concept for the future of
cognitive enhancement in other areas, including attention or
focus, using closed-loop neurostimulation technologies.
• Future steps include determining the number of contacts
needed for sensing and stimulation, and the translation
of these technologies into patients with mild cognitive
impairment (MCI) and/or Alzheimer’s dementia (AD).
Hippocampal Memory Prostheses: Neural
Code-Based DBS
A hippocampal memory prosthesis is defined as a closed-
loop system that bypasses damaged hippocampal region(s) to
restore or enhance memory functions (Berger et al., 2011). Like
closed-loop DBS systems, it consists of a recording unit (e.g.,
multi-electrode array), a signal processing/control unit, and a
stimulator (e.g., stimulating electrodes). Differing from DBS
systems, which typically deliver stereotypical stimulation patterns
(e.g., HFS or LFS) to target regions to modulate neural activities,
hippocampal memory prostheses utilize neural code-based
stimulation patterns to reinstate neural signal transmission and
thus mimic brain functions. Hippocampal memory prostheses
have been developed and tested in rodents (Song et al., 2007,
2009; Berger et al., 2011, 2012; Hampson et al., 2012a,b),
nonhuman primates (Hampson et al., 2013), and human epilepsy
patients (Song et al., 2016; Hampson et al., in preparation).
This technique is now being applied to human studies
in which multi-electrode “macro-micro” depth electrodes are
implanted in the hippocampus of epilepsy patients undergoing
Phase II invasive monitoring for seizure localization (Figure 13).
Hippocampal CA3 and CA1 neural ensembles are recorded while
patients perform a delayed match-to-sample (DMS) task. Multi-
input, multi-output (MIMO) nonlinear dynamical models are
built to describe the transformation from CA3 (input) spatio-
temporal patterns (codes) of spikes to CA1 (output) spatio-
temporal patterns (codes) of spikes using CA3 and CA1 data
recorded from success trials of DMS tasks, and further drive
stimulations to the CA1 region (Song et al., 2013, 2016). In
combination with the modeling from human data, results from
preclinical testing in rodents and nonhuman primates (Hampson
et al., 2013) demonstrate that (1) MIMO models accurately
predict CA1 codes in real-time from ongoing CA3 codes; and
(2) closed-loop electrical microstimulation of CA1 using the
MIMO-predicted CA1 codes improves DMS performance in
those same subjects, indicating improvement of workingmemory
function.
Highlights and Future Challenges
• Hippocampal neurostimulators implanted in epilepsy
patients, multi-input, multi-output (MIMO) nonlinear
dynamical models have been built to describe the
transformation from CA3 (input) spatio-temporal patterns
(codes) of spikes to CA1 (output).
• MIMO models accurately predict CA1 codes in real-time
from ongoing CA3 codes and improve DMS performance and
delayed recognition of DMS visual stimuli.
• An increased level of complexity in memory decoding is
expected going forward. Certain limitations apply to current
stimulating electrode and improved electrode design might be
necessary to facilitate research.
• Future research to determine the most effective location for
stimulation, changes in plasticity and stimulating parameters
is needed.
ETHICAL AND POLICY ISSUES
As evidenced in the this report, there are ample new
developments in DBS technology. These include increasingly
sophisticated electrodes and electrode arrays (that enable both
stimulation and recording), iterative BCI systems’ hard- and
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FIGURE 13 | Hippocampal memory prosthesis. (A) Hippocampal prosthesis restores memory functions by reinstating neural signals and thus bypassing damaged
brain region. (B) A MIMO model serves as the computational basis of hippocampal memory prostheses. (C) A MIMO model accurately predicts CA1 (output) codes
based on CA3 (input) codes in human. (D) MIMO-stimulation enhances memory functions in preclinical animal testing.
software, and closed-loop adaptive systems. As well, a building
body of research—as presented here - demonstrates the efficacy
of various forms of DBS in mitigating signs and symptoms
of disorders beyond PD, dystonia and epilepsy (e.g., Tourette
syndrome; depression; OCD; memory loss in TBI and AD). This
suggests, if not supports, an expanding translational viability
and potential value of such approaches. This widening scope
of capability and use fosters ethical and policy issues, which
can be parsed into (1) those inherent to the characteristics
of the technology and/or technique, and (2) those derived
from the uses of such technologies in medicine and other
applications in the social sphere (for complete address of specific
neuroethico-legal and social issues, see: Buniak et al., 2014;
Darragh et al., 2015; Giordano, 2017). These are not mutually
exclusive: the relative novelty of technologies and techniques
spawns questions about the intermediate and ongoing safety
and effects in practical use (Giordano, 2015). The prompts
questions of if and when these approaches will represent
an accepted standard of care for certain disorders; where
and under what conditions/contingencies DBS will be situated
in the plan/algorithm of care for these pathologies, and if
and to what extent medical and/or socio-economic and legal
means of support will be provided to enable such care—in
both the short and long term. Current problems in the
subsidy of DBS treatment of certain movement and psychiatric
disorders undergird the importance and need for continuing
discourse and deliberation focal to these issues (Rossi et al.,
2017).
As well, questions persist as to whether and how implantable
neuromodulation might affect aspects of neuropsychological
function that are associated with identity, “free will” and
autonomy, and what this incurs and infers for the ethically
sound use of DBS both to treat defined medical conditions,
as well as to potentially optimize/enhance particular aspects
of cognition, emotion and/or behavior (Giordano, 2015). We
have posited that any new developments in neurotechnology
entail effort to define and address the neuroethico-legal and
social issues that may, and are likely to be generated by such
research and its trsanslation in medical and/or other applications
(Shook and Giordano, 2015), and unapologetically reiterate
that assertion here. To effect such effort, it will be therefore
important—and necessary—to both employ extant ethical and
policy constructs and to revisit, and in some cases revise these
concepts and processes so as to better meet the exigencies
borne of emerging technology and techniques, and of the social
contingencies and concerns that affect and are affected by
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FIGURE 14 | Representation of the anonymous annual survey results, polling the participants of the DBS Think Tank on the hype cycle positions of different DBS
related neurotechnological advances and indications. On the right side, the hype cycle graph (adapted Jackie Fenn, “When to leap on the hype cycle,” Decision
Framework DF-08-6751, Research Note, GartnerGroup RAS Services, June 30, 1999 with permission) that represents the different stages of development. On the left
side, a table summarizing the weighted averages of the position of the different neurotechnological indications or uses on the hype cycle graph. Positions 0 to 6 are
color coded as noted.
their use in international contexts (Shook and Giordano, 2014;
Giordano, 2015). Our ongoing work remains dedicated to these
tasks.
SUMMARY AND CONCLUSION
In this paper, we have provided views to the relevant topics
and updates discussed at The Fifth Annual DBS Think Tank
in Atlanta, GA. Similar to prior years’ ThinkTank meetings,
an anonymous 40 question poll was sent online to assess
participants’ perspectives and attitudes toward the current and
near-term future developments and applications in the field. Sixty
two participants responded. Figure 14 presents a summary of
these responses, compares them to last year’s responses, and
depicts this year’s responses as positioned in various points upon
the hype cycle graph. It is notable that some participants’ views of
DBS applications (e.g., closed loop feedback) moved to the peak
of inflated expectations, while, others (e.g., DBS for Tourette’s)
dropped from this position on the hype cycle graph, and yet
others (e.g., Imaging to guide surgical targeting and spinal cord
stimulation for pain management) remained in the trough of
disillusionment. Consistently, the use of DBS for PD and essential
tremor has reached the plateau of productivity and among
most participants, cautious optimism remains regarding the
use of neuromodulation for several neuropsychiatric conditions,
non-neurological indications and the development of newer
technologies.
In conclusion, the Fifth Annual DBS Think Tank provided
a nexus for discussion and vector for the exchange of ideas
about the current and near-term state and direction of DBS
research, ongoing technological, scientific and clinical challenges
and opportunities, and ethical and policy concerns and possible
resolutions important to shaping the future of DBS research and
use in practice.
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